One-third of chemo drugs used off-label; China to cut drug wholesalers in reform move;

@FiercePharma: Chinese government plans to cut the number of drug wholesalers to 3K from 13K. Pharma stocks there rose on the news. More | Follow @FiercePharma

@EricPFierce: Gilead, Teva now making nice over Viread patent, ending years of litigation. News | Follow @EricPFierce

@AlisonBFierce: HealthMap has expanded its reach, allowing people to search for any of 11 vaccines available near their home. Story | Follow @AlisonBFierce

> Almost one-third of chemotherapy drugs are used off-label, a study found; 14% for uses supported by the National Comprehensive Care Network and 10% for uses without FDA or NCCN approval. Report

> The Chinese government plans to cut the number of drug wholesalers to 3,000 from 13,000, in a move that could help support pharma profits. Report

> A new European patent court specializing in pharma and life sciences is expected to be operational in 2015 under a newly finalized agreement. Report

> The FDA warned doctors not to use codeine in children who've undergone surgery to remove their tonsils or adenoids. Report

> A lack of new drugs for childhood cancers has stalled the increase in 5-year survival rates. Report

> Pfizer ($PFE) tapped Leo Burnett Worldwide to launch its over-the-counter version of Nexium, licensed from AstraZeneca ($AZN), which sells the branded version. Report

Medical Device News

 @FierceMedDev: Dune gains CE mark for next gen-breast cancer Dx tool. News | Follow @FierceMedDev

 @MarkHFierce: Hmm, the second med device venture funding in two days. This time, a focus on uterine fibroid ablation. Release | Follow @MarkHFierce

 @DamianFierce: Thanks to investor excitement, Life Technologies might now be too pricey for a sale. More | Follow @DamianFierce

> Natera launches prenatal diagnostic with big Quest co-sign. Story

> Medtronic halves estimate of device tax hit. Item

Biotech News

 @FierceBiotech: If you missed it yesterday, check out @RyanMFierce's feature on : Top 10 Biotech Techies, 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Interesting biotech model: NC development team nabs $5M angel tranche for their latest biotech play. Story | Follow @JohnCFierce

> Chelsea rebounds after FDA agrees to take a look at new Northera data. News

> Star-crossed Merck reorganizes troubled biosimilars effort around Samsung pact. Report

> MDxHealth hits testing milestone with prostate cancer epigenetic Dx. Item

Drug Delivery News

> Lentigen's stem cell delivery for brain tumors nets FDA orphan status. News

> PolyActiva seeks drug partner for new intraocular delivery implant. Report

> Oramed presses forward into PhII with oral insulin pill. Story

> EpiVax, Novozymes fuse drug, delivery protein with $3B market at hand. Item

Biomarkers News

> NIH pours $900K into Parkinson's biomarker research. News

> Alzheimer's biomarkers indicate dementia advancement. More

> Mayo study spotlights new biomarkers for quick kidney injury alert. Report

> NYU investigative team on the trail of PTSD biomarkers. Article

> Nanomix plans test of triple biomarker heart attack Dx. Story

And Finally... The extraordinary science of addictive junk food. Report (sub. req.)

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.